老年2型糖尿病患者使用二肽基肽酶4抑制剂的疗效和安全性评价

Efficacy and safety of DPP-4 inhibitors in elderly patients with type 2 diabetes

二肽基肽酶4(DPP-4)抑制剂是一类基于肠促胰素的新型口服降糖药物,我国已有5种DPP-4抑制剂被批准上市。近年来,DPP-4抑制剂被国内外糖尿病治疗指南广泛推荐。由于老年人是T2DM主要患病人群,使用DPP-4抑制剂的安全性尤为重要。本文进行文献检索及分析,旨在探索老年人使用DPP-4抑制剂的有效性和安全性,为临床提供依据。

DPP-4 inhibitors are a new type of oral glucose lowering drugs based on pancreatic glucagon. There are 5 kinds of DPP-4 inhibitors that are approved in our country. Currently, DPP-4 inhibitors have been widely recommended by domestic and international diabetes treatment guidelines. The safety of DPP-4 inhibitors is particularly important in elderly patients because this is the main population in type 2 diabetes. Here,we reviewed the literatures,explore the effectiveness and safety of DPP-4 inhibitors in elderly population, and provide evidence for clinical practice.